New £750 million UK cancer strategy to fund drugs and stimulate molecular diagnostics
This article was originally published in Scrip
The department of health in the UK has announced new plans, to be allocated £750 million over four years, for improving outcomes in cancer. They largely hinge on earlier and better diagnosis, improved screening, placing greater emphasis on prevention, and improving access to high quality care, support and treatment. The latter places a high emphasis on drugs, although there are few surprises about what the government has in mind.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.